论文部分内容阅读
目的观察维拉帕米终止室性心动过速 (室速 )的疗效及安全性。方法对 2 8例单形性及多形性室速经使用Ⅰ、Ⅱ、Ⅲ类抗心律失常药治疗无效后 ,改用维拉帕米稀释后静脉注射 ,每次 5～ 10mg ,终止室速后改用 10～ 2 0mg加 2 5 0ml液体静脉滴注维持 ,2 4～ 48小时后根据病情改口服 40～ 80mg ,3次 /d ,并密切观察心率、血压、心脏功能变化。结果终止室速 2 4例 ,无效 3例 ,死亡 1例。未见严重的缓慢性心律失常、血压下降及心衰加重。结论维拉帕米对于用Ⅰ、Ⅱ、Ⅲ类抗心律失常药治疗无效的室速有较好的疗效 ,且副作用少 ,安全性较好。但其远期疗效尚难肯定
Objective To observe the efficacy and safety of verapamil in terminating ventricular tachycardia (VT). Methods 28 cases of monomorphic and pleomorphic ventricular tachycardia were treated with antiarrhythmic drugs of type Ⅰ, Ⅱ and Ⅲ after treatment with verapamil. After intravenous injection of verapamil (5 ~ 10 mg), the ventricular tachycardia was terminated After the switch to 10 ~ 20mg plus 250ml liquid intravenous infusion, 24 ~ 48 hours after oral administration of 40 ~ 80mg, 3 times / d, and close observation of heart rate, blood pressure, cardiac function changes. Results The termination of ventricular tachycardia in 24 cases, 3 cases, 1 case of death. No severe bradyarrhythmia, decreased blood pressure and increased heart failure. Conclusion Verapamil has better curative effect on ventricular tachycardia induced by type Ⅰ, Ⅱ and Ⅲ antiarrhythmic drugs with fewer side effects and better safety. However, its long-term efficacy is hard to be sure